Lita S Suwandi

8158612, Apr 17, 2012

Dec 22, 2008

12/341068

Gregory E. Agoston - Germantown MD, US
Jamshed H. Shah - Brookeville MD, US
Lita Suwandi - Alexandria VA, US
Theresa M. LaVallee - Rockville MD, US
Anthony M. Treston - Rockville MD, US

EntreMed, Inc. - Rockville MA

A61K 31/56

514169, 514182

Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae:.

20050203075, Sep 15, 2005

Mar 11, 2005

11/077977

Gregory Agoston - Germantown MD, US
Jamshed Shah - Brookeville MD, US
Lita Suwandi - Alexandria VA, US
Theresa LaVallee - Rockville MD, US
Anthony Treston - Rockville MD, US

A61K031/56
C07J001/00

514182000, 552626000

Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ris selected from —OCH, —OCHCHor —CCCH; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.

20060063930, Mar 23, 2006

Aug 19, 2005

11/208460

Gregory Agoston - Rockville MD, US
Todd Hembrough - Damascus MD, US
Theresa LaVallee - Rockville MD, US
Jamshed Shah - Brookeville MD, US
Lita Suwandi - Alexandria VA, US
Anthony Treston - Rockville MD, US

C07D 261/18
C07D 235/30
C07D 403/02

544162000, 568840000, 544387000, 544360000, 544370000, 548307400, 548248000, 548371700

Compositions and methods comprising proteinase activated receptor antagonists are provided. More particularly, the present invention relates to the use of proteins, peptides and molecules that bind to proteinase activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.

20070004689, Jan 4, 2007

Jul 19, 2006

11/489263

Gregory Agoston - Rockville MD, US
Jamshed Shah - Brookeville MD, US
Lita Suwandi - Alexandria VA, US
Theresa LaVallee - Rockville MD, US
Anthony Treston - Rockville MD, US

A61K 31/58
A61K 31/56
C07J 21/00
C07J 1/00

514169000, 514173000, 552626000, 540032000

Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ris selected from —OCH, —OCHCHor —CCCH; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, or >C(H)-dioxolane, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.

20090029992, Jan 29, 2009

Jun 11, 2008

12/137355

GREGORY E. AGOSTON - Rockville MD, US
Anthony M. Treston - Rockville MD, US
Gaetan Ladouceur - Rockville MD, US
Lita Suwandi - Alexandria VA, US

A61K 31/5377
C07D 403/14
C07D 403/02
A61P 35/00
A61K 31/506
A61K 31/496
C07D 413/14

5142358, 544295, 544328, 544122, 51425219, 51425214, 514256

Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

20110318393, Dec 29, 2011

Nov 23, 2009

13/128656

Gaetan Ladouceur - Raleigh NC, US
Gregory A. Agosto - Rockville MD, US
Jamshed H. Shah - Silver Spring MA, US
Lita Suwandi - Cary NC, US
Nnamdi Ofoegbu - Cockeysville MD, US

MIIKANA THERAPEUTICS, INC. - Rockville MD

A61K 9/14
C07D 403/14
C07D 413/14
A61K 31/506
A61K 31/5377
C07D 405/14
A61P 29/00
A61P 25/00
A61P 35/00
A61P 9/00
A61P 37/08
A61P 11/06
A61P 5/00
A61P 35/02
A61P 17/10
A61P 31/04
A61P 31/22
A61P 27/06
A61P 33/02
A61P 19/02
A61P 7/06
A61P 17/00
A61P 17/06
C07D 401/14

424400, 544328, 544295, 544122, 5142102, 514256, 51425218, 5142365, 51425219

Provided are substituted pyrazole compounds which are useful as protein kinase inhibitors, compositions comprising the compounds, and methods of use thereof. The protein kinase inhibitors are particularly for inhibition of Aurora A (Aurora-2) protein kinase and are useful in the treatment of diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

20220298160, Sep 22, 2022

Aug 28, 2020

17/635776

- Brentford, Middlesex, GB
- Wilmington DE, US
Lita S. SUWANDI - Research Triangle Park NC, US
David TEMELKOFF - Research Triangle Park NC, US
Emile Johann VELTHUISEN - Collegeville NC, US

GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED - Brentford, Middlesex
VIIV HEALTHCARE COMPANY - Wilmington DE

C07D 473/34

The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

20210078988, Mar 18, 2021

Jun 27, 2018

16/618830

- Brentford, Middlesex, GB
Wieslaw Mieczyslaw KAZMIERSKI - Research Triangle Park NC, US
John Franklin MILLER - Research Triangle Park NC, US
Vicente SAMANO - Research Triangle Park NC, US
Lita SUWANDI - Research Triangle Park NC, US
David TEMELKOFF - Research Triangle Park NC, US
Yoshiaki WASHIO - Stevenage, Hertfordshire, GB
Bing XIA - Cambridge MA, US

C07D 413/14
C07D 409/12
C07D 211/26
C07D 409/14
C07D 401/06
C07D 413/06
C07D 413/12
C07D 401/12
C07D 405/12
C07D 417/12
C07D 211/96

Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.